Cleara Biotech Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
Cleara Biotech General Information
Description
Operator of a biotechnology company intended to eliminate senescent cells to treat age-related pathologies. The company offers therapeutics that can be used to remove senescence-like cancer cells that are a cause of therapy resistance in terminal cancer, enabling physicians to treat their patients effectively.
Contact Information
Website
www.clearabiotech.comCorporate Office
- Yalelaan 62
- 3584 CM Utrecht
- Netherlands
Corporate Office
- Yalelaan 62
- 3584 CM Utrecht
- Netherlands
Cleara Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 02-Feb-2026 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC | 31-Jul-2024 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 28-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series 3) | 31-Dec-2021 | $2.49M | $2.49M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 23-Oct-2018 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cleara Biotech Patents
Cleara Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4249912-A1 | Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal | Pending | 24-Mar-2022 | ||
| EP-4500174-A1 | Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal | Pending | 24-Mar-2022 | ||
| US-20250189516-A1 | Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal | Pending | 24-Mar-2022 | ||
| WO-2023180570-A1 | Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal | Inactive | 24-Mar-2022 | ||
| US-20240197824-A1 | Anti-senescence compounds and uses for the treatment of cancer | Pending | 21-Feb-2020 | A61K38/1761 |
Cleara Biotech Signals
Cleara Biotech Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CoastCap | Family Office | Minority | ||
| Korify Capital | Venture Capital | Minority | ||
| Infinitas Capital | Family Office | Minority | ||
| iSTAR (UAV Solutions) | Corporation | Minority | ||
| Longevitytech.fund | Venture Capital | Minority |
Cleara Biotech FAQs
-
When was Cleara Biotech founded?
Cleara Biotech was founded in 2018.
-
Where is Cleara Biotech headquartered?
Cleara Biotech is headquartered in Utrecht, Netherlands.
-
What is the size of Cleara Biotech?
Cleara Biotech has 9 total employees.
-
What industry is Cleara Biotech in?
Cleara Biotech’s primary industry is Drug Discovery.
-
Is Cleara Biotech a private or public company?
Cleara Biotech is a Private company.
-
What is Cleara Biotech’s current revenue?
The current revenue for Cleara Biotech is .
-
How much funding has Cleara Biotech raised over time?
Cleara Biotech has raised $4.99M.
-
Who are Cleara Biotech’s investors?
CoastCap, Korify Capital, Infinitas Capital, iSTAR (UAV Solutions), and Longevitytech.fund are 5 of 11 investors who have invested in Cleara Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process